APA (7th ed.) Citation

Choi, C. H., Ray-Coquard, I., Rubio, M. J., Paoletti, X., Hudson, E., Lorusso, D., . . . Lee, J. (2024). DOMENICA study (GINECO-EN105b/ENGO-Ten13): Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1). Journal of Gynecologic Oncology, 35, 19. https://doi.org/10.3802/jgo.2024.35.S2.P1

Chicago Style (17th ed.) Citation

Choi, Chel Hun, et al. "DOMENICA Study (GINECO-EN105b/ENGO-Ten13): Randomized Phase III Trial in MMR Deficient (MMRd) Endometrial Cancer (EC) Patients Comparing Chemotherapy (CT) Alone Versus Dostarlimab in First Line Advanced/metastatic Setting (APGOT-EN1)." Journal of Gynecologic Oncology 35 (2024): 19. https://doi.org/10.3802/jgo.2024.35.S2.P1.

MLA (9th ed.) Citation

Choi, Chel Hun, et al. "DOMENICA Study (GINECO-EN105b/ENGO-Ten13): Randomized Phase III Trial in MMR Deficient (MMRd) Endometrial Cancer (EC) Patients Comparing Chemotherapy (CT) Alone Versus Dostarlimab in First Line Advanced/metastatic Setting (APGOT-EN1)." Journal of Gynecologic Oncology, vol. 35, 2024, p. 19, https://doi.org/10.3802/jgo.2024.35.S2.P1.